Login to Your Account

GTx Nixes Toremifene After Ipsen Terminates Partnership

By Marie Powers

Thursday, March 3, 2011
GTx Inc. plans to walk away from toremifene after the company "mutually agreed to terminate" its collaboration with Ipsen Group SA to develop and commercialize the drug, GTx CEO Mitchell Steiner told BioWorld Today.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription